首页 > 专家库
刘亚妮

领域:生物产业 学校:华中科技大学职称:副教授

药物代谢动力学;免疫抑制剂精准治疗临床实践研究;遗传药理学...

具体了解该专家信息,请致电:027-87555799 邮箱 haizhi@uipplus.com

教育背景

2006年华中科技大学同济医学院药学院硕士毕业

工作经历

于附属协和医院药学部实验室工作至今。

项目课题经历

药物代谢动力学;免疫抑制剂精准治疗临床实践研究;遗传药理学

论文、成果、著作等

1. Tolerability and pharmacokinetics of hydronidone, an antifibrotic agent for hepatic fibrosis, after single and multiple doses in healthy subjects: an open-label, randomized, dose-escalating, first-in-human study. Eur J Drug Metab Pharmacokinet. 2017; 42(1):37-48.

2. Association of RAC1 gene polymorphisms with primary end-stage renal disease in chinese renal recipients. PLoS One. 2016; 11(2): e0148270.

3. Identification and association of RAC1 gene polymorphisms with mRNA and protein expression levels of Rac1 in solid organ (kidney, liver, heart) transplant recipients. Mol Med Rep. 2016;14(2):1379-1388.

4. Impact of quercetin‑induced changes in drug‑metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats. Mol Med Rep. 2016;14(4):3073-3085.

5. Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study. Eur J Drug Metab Pharmacokinet. 2015; 40(4):443-451.

6. Tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy chinese subjects. Clin Ther. 2014; 36(6):940-952

7. Tolerability and pharmacokinetics of biapenem following single and multiple intravenous administrations in healthy chinese subjects: an open-label, randomized, single-center study. Drug Res (Stuttg). 2013; 63(8): 396–403.

8. Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone [rhpth(1-84)] after single- and multiple-dose subcutaneous administration in healthy chinese volunteers. Basic Clin Pharmacol Toxicol. 2012; 110(2): 154-161.

9. A simple and sensitive liquid chromatographic technique for the determination of cefotetan disodium in human plasma and its application in a pharmacokinetic study. J Huazhong Univ Sci Technolog Med Sci. 2012; 32(5):779-784.

10. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers. Arzneimittelforschung. 2012; 62(2): 75-82.

11. Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy chinese volunteers: a randomized, open-label, single- and multiple-dose study. Clin Ther. 2010; 32(10):1832-1841.

12. Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in healthy fasting chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. Clin Ther. 2010; 32(11):1977-1986.

13. RAC1基因多态性对Rac1-GTP蛋白表达水平的影响. 中国免疫学杂志. 2016; 32(12):1729-1733.

14. LC-MS/MS法测定人血浆中左舒必利含量的不确定度评定. 中国药师. 2016; 19(12):2369-2372.

15. 肿瘤转移抑制基因Nm23多态性在湖北汉族肾移植患者中的分布. 中国医院药学杂志. 2015; 35(1):1-5.

16. Rac1基因多态性在湖北汉族肾移植患者中的分布. 中国药学杂志. 2014; 49(21):1923-1927.

17. 规范使用抗菌药对预防I类切口手术部位感染的效果. 中国药师,2014,17(4):644-646.

18. 高效液相色谱法测定人血浆中头孢替坦二钠含量的不确定度. 中国医院药学杂志. 2013; 33(20):1695-1698.

19. 注射用重组人甲状旁腺素(1-34)在中国健康人体内的药动学. 中国医院药学杂志. 2013; 33(23):1962-1965.

20. 高效液相色谱法测定盐酸法舒地尔注射液中盐酸法舒地尔的含量及有关物质. 中国医院药学杂志. 2013; 33(24):2085-2087.

21. 毛细管气相色谱法测定盐酸吉西他滨中5种有机溶剂残留量. 中国医院药学杂志. 2013; 33(14):1199-1201.

22. 高效液相色谱法测定姜黄素清蛋白纳米粒中药物含量与包封率. 医药导报. 2013; 32(7):936-938.

23. HPLC法测定欢快虫草口服液中腺苷的含量. 中国药师. 2013; 16(4):570-572.

24. 黄芩素对β-淀粉样蛋白纤维化及其细胞毒性的影响. 医药导报. 2013; 32(3):303-306.

25. HPLC法测定吡诺克辛钠的含量及有关物质. 中国药师. 2013; 16(1):66-68.

26. 辛伐他汀片及其活性代谢产物在中国健康人体的药动学和生物等效性评价. 中国医院药学杂志. 2012; 32(19):1530-1533.

27. LC-MS/MS测定人血浆中辛伐他汀及其活性代谢物的含量. 药物分析杂志. 2012; 32(9):1617-1622.

28. 注射用头孢替坦二钠在中国健康人体内的药动学. 中国药学杂志. 2012; 47(2):132-136.

29. 共研磨法改善水飞蓟素固体分散体的溶出度. 中国医院药学杂志. 2012; 32(17):1361-1365.

30. 气相色谱法同时测定无极膏中5个挥发性有效成分的含量. 药物分析杂志. 2012; 32(3):406-409.

31. 高效液相色谱法同时测定葛根提取物中5种异黄酮的含量. 中国医院药学杂志. 2012; 32(5):344-346.

32. 注射用兰索拉唑在中国健康人体内的药动学. 中国医院药学杂志. 2011; 31(4):280-283.

专利、著作版权等

声明:本站专家信息来源于各高校官网。